Clinical review of mustard lung

Iranian Journal of Medical Sciences

Volumn 32, Issue 2, 2007, Pages 58-65

  Ghanei, Mostafa ^a   Adibi, I ^a  

^a BAQIYATALLAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Chemical weapon; Mustard gas; Respiratory system; Sulfur mustard; Weapon of mass destruction

Indexed keywords

ANTIOXIDANT; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL; IPRATROPIUM BROMIDE; MACROLIDE; MUSTARD GAS; SALBUTAMOL;

ASTHMA; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; BRONCHUS STENOSIS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DYSPNEA; EXPOSURE; FIBROSING ALVEOLITIS; HEMATOLOGY; HUMAN; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG FUNCTION TEST; MEDICAL LITERATURE; NONHUMAN; PATHOLOGY; PNEUMONIA; REVIEW; SPIROMETRY; SYMPTOM; THORAX RADIOGRAPHY;

EID: 39449092509     PISSN: 02530716     EISSN: 17353688     Source Type: Journal    
DOI: None     Document Type: Review

References (55)

1. Hefazi M, Maleki M, Mahmoudi M, et al. Delayed complications of sulfur mustard poisoning in the skin and the immune system of Iranian veterans 16-20 years after exposure. Int J Dermatol 2006; 45:1025-31.
2. Sidell FR, Urbanetti JS, Smith WJ. Vesicants. In: Zajtchuk R, Bellamy RF, eds. Medical Aspects of Chemical and Biological Warfare. Washington, DC: Office of the Surgeon General-Department of the Army; United States of America; 1997. p. 197-228.
3. Prentiss AM. Vesicant Agents. In: Chemicals in Warfare: a Treatise on Chemical Warfare. New York; USA; McGraw-Hill; 1937. p. 177-300.
4. United Nations Security Council. Report of the mission despatched by the Secretary General to investigate allegations of the use of chemical weapons in the conflict between the Islamic Republic of Iran and Iraq (S/18852). New York: UN; 1987.
5. Kehe K, Szinicz L. Medical aspects of sulphur mustard poisoning. Toxicology 2005; 214: 198-209.
6. Balali M. Clinical and laboratory findings in Iranian fighters with chemical gas poisoning. In: Heyndrickx, A, ed. Proceedings of the First World Congress on New Compounds in Biological and Chemical Warfare. Ghent, Belgium: Rijksuniversiteit; 1984. p. 254-9.
7. Willems JL. Clinical management of mustard gas casualties. Ann Med Mil Belg 1989; 3: S1-S61.
8. Balali-Mood M, Hefazi M. Comparison of early and late toxic effects of sulfur mustard in Iranian veterans. Basic Clin Pharmacol Toxicol 2006; 99: 273-82.
9. Marrs TC, Maynard RL, Sidell FR. Chemical warfare agents: toxicology and treatment. John Wiley and Sons, Chichester, UK, 1996.
10. Khateri S, Ghanei M, Keshavarz S, et al. Incidence of lung, eye, and skin lesions as late complications in 34,000 Iranians with wartime exposure to mustard agent. J Occup Environ Med 2003; 45: 1136-43.
11. Statistic Annals Booklet of the Janbazan Organization. Clinical status of chemical warfare victims. Janbazan Organization, Health and Treatment Department; 2000.
12. Warthin AS, Weller CV, Herrman GR. The ocular lesions produced by dichlorethyl sulfide (mustard gas). J Lab Clin Med 1918; 4: 785-832.
13. Sidell FR. Clinical notes on chemical casualty care, USAARMICD technical memorandum. US Army Medical Research Institute of Chemical Defense: Aberdeen, 1990.
14. Freitage L, Firusian N, Stamatis G, Greschuchna D. The role of bronchoscopy in pulmonary complications due to mustard gas inhalation. Chest 1991; 100: 1436-41.
15. Papirmeister B, Feister AJ, Robinson SI, Ford RD. Medical defense against mustard gas: Toxic mechanisms and harmacological implications. CRC Press, Boca Raton, Florida, USA, 1991.
16. Balali-Mood M, Hefazi M, Mahmoudi M, et al. Long-term complications of sulfur mustard poisoning in severely intoxicated Iranian veterans. Fundam Clin Pharmacol 2005; 19: 713-21.
17. Balali-Mood M, Hefazi M. The pharmacology, toxicology, and medical treatment of sulphur mustard poisoning. Fundam Clin Pharmacol 2005; 19: 297-315.
18. Ghanei M, Fathi H, Mohammad MM, et al. Long-term respiratory disorders of claimers with subclinical exposure to chemical warfare agents. Inhal Toxicol 2004; 16: 491-5.
19. Ghanei M, Hosseini AR, Arabbaferani Z, ShahKarami E. Evaluation of Chronic Cough in Chemical Chronic Bronchitis Patients. Environmental Toxicology & Pharmacology 2005; 20: 6-10.
20. Sohrabpour H, Masjedi M R, Bahadori M. Late complications of sulfur mustard in respiratory system. Med J Islam Repub Iran 1988; 2: 171-3.
21. Hefazi M, Attaran D, Mahmoudi M, Balali-Mood M. Late respiratory complications of mustard gas poisoning in Iranian veterans. Inhal Toxicol 2005; 17: 587-92.
22. Emad A, Rezaian GR. The Diversity of effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: Analysis of 197 cases. Chest 1997; 112: 734-8.
23. Aslani J. Late Respiratory complications of sulfur mustard. In: Prevention and treatment of complications of chemical warfare agents. Ed: A.M. Cheraghali. Chemical Warfare Research Centre, Tehran; Iran; 2000. p. 76-9.
24. Ghanei M, Akhlaghpoor S, Moahammad MM, Aslani J. Tracheobronchial stenosis following sulfur mustard inhalation. Inhal Toxicol 2004; 16: 845-9.
25. Heidarnejad H, Zendehdel N, Dastgiri S. Temporal trend of clinical and spirometric parameters in mustard gas victims: A ten year study. Arch Iran Med 1988; 1: 13-6.
26. Beheshti J, Mark EJ, Hosein Akbaei HM, et al. Mustard Lung Secrets: Long Term Clinicopathological Study Following Mustard Gas Exposure. Pathol Res Pract 2006; 202: 739-44.
27. Ghanei M, Harandi AA. Long term consequences from exposure to sulfur mustard: a review. Inhal Toxicol 2007; 19: 451-6.
28. Emad AF, Rezaian GR, Hosseini K, Ghayyoomi SMA. Chronic pulmonary sequelae of sulfur mustard gas exposure in man: A report of 36 Cases. Irn J Med Sci 1995; 20: 1-4.
29. Bagheri M H, Hosseini S K, Mostafavi SH, Alavi SA. High-resolution CT in chronic pulmonary changes after mustard gas exposure. Acta Radiol 2003; 44: 241-5.
30. Ghanei M, Mokhtari M, Mohammad MM, Aslani J. Bronchiolitis obliterans following exposure to sulfur mustard: chest high resolution computed tomography. Eur J Radiol 2004; 52: 164-9.
31. Bijani Kh, Moghadamnia AA. Long-term effects of chemical weapons on respiratory tract in Iraq-Iran war victims living in Babol (North of Iran). Ecotoxicol Environ Saf 2002; 53: 422-4.
32. Emad A, Rezaian GR. Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Chest 1999; 115: 1346-51.
33. Emad A, Emad Y. Levels of cytokine in bronchoalveolar lavage (BAL) fluid in patients with pulmonary fibrosis due to sulfur mustard gas inhalation. J Interferon Cytokine Res 2007; 27: 38-43.
34. Aghanouri R, Ghanei M, Aslani J, et al. Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15 years after exposure to sulfur mustard. Am J Physiol Lung Cell Mol Physiol 2004; 287: L1160-4.
35. Eickelberg O, Köhler E, Reichenberger F, et al. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am J 1999; 276: L814-24.
36. Khalil N, O'Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5: 155-62.
37. El-Gamel A, Sim E, Hasleton P, Hutchinson J, et al. Transforming growth factor beta (TGF-beta) and obliterative bronchiolitis following pulmonary transplantation. J Heart Lung Transplant 1999; 18: 828-37.
38. Mahmoudi M, Hefazi M, Rastin M, Balali-Mood M. Long-term hematological and immunological complications of sulfur mustard poisoning in Iranian veterans. Int Immunopharmacol 2005; 5: 1479-85.
39. Krumbhaar EB, Krumbhaar HD. The blood and bone marrow in yellow cross gas (mustard gas) poisoning. J Med Res 1919; 40: 497-506.
40. Hassan ZM, Ebtekar M. Immunological consequence of sulfur mustard exposure. Immunol Lett 2002; 83:151-2.
41. Zandieh T, Marzaban S, Tarabadi F, Ansari H. Defects of cellmediated immunity in mustard gas injury after years. Scand J Immunol 1990; 32: 423.
42. Ghotbi L, Hassan Z. The immunostatus of natural killer cells in people exposed to sulfur mustard. Int Immunopharmacol 2002; 2:981-5.
43. Yokogama MW. Recognition of natural killer cells. Curr Opin Immunol 1993; 5: 67-73.
44. Thomason JW, Rice TW, Milstone AP. Bronchiolitis obliterans in a survivor of a chemical. weapons attack. JAMA 2003; 290: 598-9.
45. Elkin SL, Nicholson AG, du Bois RM. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Semin Respir Crit Care Med 2001; 22: 387-98.
46. Wall CP, Gaensler EA, Carrington CB, Hayes JA. Comparison of transbronchial and open biopsies in chronic infiltrative lung diseases. Am Rev Respir Dis. 1981; 123: 280-5.
47. Chuang MT, Raskin J, Krellenstein DJ, Teirstein AS. Bronchoscopy in diffuse lung disease: evaluation by open lung biopsy in nondiagnostic transbronchial lung biopsy. Ann Otol Rhinol Laryngol 1987; 96: 654-7.
48. Ghanei M, Khedmat H, Mardi F, Hosseini A. Distal esophagitis in patients with mustardgas induced chronic cough. Dis Esophagus. 2006; 19: 285-8.
49. Hosseini K, Alavi S, Abedi A R. Reversibility of airflow obstruction in chronic obstructive pulmonary disease secondary to sulfur mustard gas injury. Arch Iran Med 1999; 2: 178-80.
50. Sohrabpour H, Roshan-Zamir F, Aminorroaya AP, Pourgholami MH. Comparison of acute bronchodilatory effects of inhaled Sulbutamol and Combivent in mustard gas victims. Iran J Med Sci 1996; 21: 29-34.
51. Ghanei M, Shohrati M, Harandi AA, et al. Inhaled corticosteroids and long-acting beta 2-agonists in treatment of patients with chronic bronchiolitis following exposure to sulfur mustard. Inhal Toxicol. 2007; 19: 889-94.
52. Ghanei M, Khalili AR, Arab MJ, et al. Diagnostic and therapeutic value of short-term corticosteroid therapy in exacerbation of mustard gas-induced chronic bronchitis. Basic Clin Pharmacol Toxicol 2005; 97: 302-5.
53. Ghanei M, Abdolmaali K, Aslani J. Efficacy of concomitant administration of clarythromycin and Acetylcysteine in bronchiolitis obliterans in seventeen sulfur mustard-exposed patients: An open-Label study. Current therapeutic research 2004; 65: 495-504.
54. Crouch E. Pathobiology of pulmonary fibrosis. Am J Physiol 1990; 259: L159-84.
55. Ghanei M, Panahi Y, Mojtahedzadeh M, et al. Effect of gamma interferon on lung function of mustard gas exposed patients, after 15 years. Pulm Pharmacol Ther 2006; 19: 148-53.